Peng Jiang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peng Jiang has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Chunxia Gong
Department of Obstetrics and Gynecology, Women and Children’s Hospital of Chongqing Medical University
9 shared publicationsChenfan Tian
The First Affiliated Hospital of Chongqing Medical University
8 shared publicationsYuan Tu
The First Affiliated Hospital of Chongqing Medical University
8 shared publications- Yunfeng Zheng
Department of Gynecology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China
7 shared publications Jiaxin Yu
Chongqing Key Laboratory of Maternal and Fetal Medicine, Department of Obstetrics and Gynecology, The First Affiliated Hospital of Chongqing Medical University
6 shared publications- Rui Yuan
The First Affiliated Hospital of Chongqing Medical University
6 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1930179
A nomogram integrating YTHDC2 expression and clinicopathological parameters for predicting endometrial cancer recurrence: a multicenter retrospective study
Background: Endometrial cancer (EC) is one of the most common gynecological malignancies worldwide, with persistently rising incidence and mortality. Reliable molecular biomarkers for predicting EC recurrence remain lacking. This study aimed to develop a nomogram integrating YTHDC2 expression with clinicopathological parameters to predict postoperative recurrence-free survival (RFS) in EC patients. Methods: A total of 520 stage I–III EC patients undergoing initial standard surgical treatment were enrolled as the training cohort, and 243 patients from three independent hospitals constituted the validation cohort. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors for RFS in the training cohort, and a nomogram was constructed accordingly. Internal validation was conducted using the concordance index (C-index) and calibration curves in the training cohort, and external validation was performed in the validation cohort. Risk stratification was based on the Nomogram-predicted 3-year RFS probability, and Kaplan–Meier curves were used to evaluate the clinical utility of the model. The nomogram’s discriminative performance was further compared with three published EC prediction models. Results: Univariate and multivariate Cox regression analyses identified age (HR = 2.02, P = 0.006), International Federation of Gynecology and Obstetrics (FIGO) stage (HR = 4.20, P < 0.001), lymphovascular space invasion (LVSI; HR = 1.81, P = 0.022), CA125 level (HR = 1.66, P = 0.048), depth of myometrial invasion (HR = 1.68, P = 0.039), histological type (HR = 3.42, P < 0.001), p53 protein status (HR = 2.61, P < 0.001), and YTHDC2 high expression level (HR = 0.26, P < 0.001) as independent prognostic factors for RFS. A nomogram incorporating these eight factors was constructed to predict RFS in EC. Internal and external calibration curves demonstrated good agreement between predicted and observed outcomes. The model achieved a C-index of 0.892 in the training cohort and 0.859 in the validation cohort, significantly outperforming single-indicator models. It also surpassed three published EC prediction models in both cohorts. The nomogram consistently outperformed single-indicator models in predicting 1-, 3-, and 5-year RFS. Conclusion: The nomogram integrating YTHDC2 expression with clinicopathological parameters demonstrated favorable accuracy in predicting RFS for patients with EC and may effectively guide long-term prognostic management.
- 19 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1930179
Open AccessA nomogram integrating YTHDC2 expression and clinicopathological parameters for predicting endometrial cancer recurrence: a multicenter retrospective study
Background: Endometrial cancer (EC) is one of the most common gynecological malignancies worldwide, with persistently rising incidence and mortality. Reliable molecular biomarkers for predicting EC recurrence remain lacking. This study aimed to develop a nomogram integrating YTHDC2 expression with clinicopathological parameters to predict postoperative recurrence-free survival (RFS) in EC patients. Methods: A total of 520 stage I–III EC patients undergoing initial standard surgical treatment were enrolled as the training cohort, and 243 patients from three independent hospitals constituted the validation cohort. Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors for RFS in the training cohort, and a nomogram was constructed accordingly. Internal validation was conducted using the concordance index (C-index) and calibration curves in the training cohort, and external validation was performed in the validation cohort. Risk stratification was based on the Nomogram-predicted 3-year RFS probability, and Kaplan–Meier curves were used to evaluate the clinical utility of the model. The nomogram’s discriminative performance was further compared with three published EC prediction models. Results: Univariate and multivariate Cox regression analyses identified age (HR = 2.02, P = 0.006), International Federation of Gynecology and Obstetrics (FIGO) stage (HR = 4.20, P < 0.001), lymphovascular space invasion (LVSI; HR = 1.81, P = 0.022), CA125 level (HR = 1.66, P = 0.048), depth of myometrial invasion (HR = 1.68, P = 0.039), histological type (HR = 3.42, P < 0.001), p53 protein status (HR = 2.61, P < 0.001), and YTHDC2 high expression level (HR = 0.26, P < 0.001) as independent prognostic factors for RFS. A nomogram incorporating these eight factors was constructed to predict RFS in EC. Internal and external calibration curves demonstrated good agreement between predicted and observed outcomes. The model achieved a C-index of 0.892 in the training cohort and 0.859 in the validation cohort, significantly outperforming single-indicator models. It also surpassed three published EC prediction models in both cohorts. The nomogram consistently outperformed single-indicator models in predicting 1-, 3-, and 5-year RFS. Conclusion: The nomogram integrating YTHDC2 expression with clinicopathological parameters demonstrated favorable accuracy in predicting RFS for patients with EC and may effectively guide long-term prognostic management.
- Open Access
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1905624
AKNA serves as a prognostic biomarker and restrains endometrial cancer progression via STING activation and macrophage reprogramming
Background: AKNA, an AT-hook transcription factor, plays a critical role in cancer development. However, its prognostic value and biological function in endometrial cancer (EC) remain unclear. Methods: To systematically investigate AKNA in EC, we integrated multi-omics data (The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and single-cell transcriptomics), dual independent clinical cohorts (TCGA-UCEC dataset and two institutional cohorts), and in vitro / in vivo experimental models. Immunohistochemistry, RT-qPCR and Western blotting were used for expression validation. Functional assays, including lentiviral-mediated AKNA knockdown/overexpression, CCK-8, scratch-wound, Transwell, flow cytometry, and colony formation assays were conducted to assess the effects of AKNA modulation on proliferation, migration, invasion, epithelial-mesenchymal transition, chemosensitivity and macrophage polarization. Mechanistically, chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq), ChIP-qPCR, and dual-luciferase reporter assays were employed to define the transcriptional regulation of stimulator of interferon genes (STING) by AKNA. A prognostic nomogram integrating AKNA expression with clinicopathological features was developed and externally validated in independent cohorts. Results: AKNA was significantly downregulated in EC tissues compared with normal endometrium, which was associated with advanced International Federation of Gynecology and Obstetrics stage, aggressive histological subtypes, and poor prognosis. AKNA knockdown promoted EC cell proliferation, migration, invasion, and epithelial-mesenchymal transition, while enhancing M2 macrophage polarization and reducing sensitivity to paclitaxel and potentially compromising anti-tumor innate immunity. Conversely, AKNA overexpression or STING activation by cyclic GMP–AMP reversed these malignant phenotypes. Mechanistically, AKNA directly bound to the STING promoter and transcriptionally activated STING, thereby inducing TANK-binding kinase 1 and interferon regulatory factor 3 phosphorylation. The nomogram combining AKNA with clinicopathological features demonstrated high accuracy in predicting EC recurrence and outperformed single-variable models in both training and validation cohorts. Conclusions: AKNA deficiency promotes EC progression by transcriptionally suppressing STING and driving M2 macrophage polarization. AKNA serves as a robust prognostic biomarker and predictive indicator for chemotherapy and innate immune modulation, offering a promising therapeutic target for precision treatment of EC.
- 5 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1905624
Open AccessAKNA serves as a prognostic biomarker and restrains endometrial cancer progression via STING activation and macrophage reprogramming
Background: AKNA, an AT-hook transcription factor, plays a critical role in cancer development. However, its prognostic value and biological function in endometrial cancer (EC) remain unclear. Methods: To systematically investigate AKNA in EC, we integrated multi-omics data (The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and single-cell transcriptomics), dual independent clinical cohorts (TCGA-UCEC dataset and two institutional cohorts), and in vitro / in vivo experimental models. Immunohistochemistry, RT-qPCR and Western blotting were used for expression validation. Functional assays, including lentiviral-mediated AKNA knockdown/overexpression, CCK-8, scratch-wound, Transwell, flow cytometry, and colony formation assays were conducted to assess the effects of AKNA modulation on proliferation, migration, invasion, epithelial-mesenchymal transition, chemosensitivity and macrophage polarization. Mechanistically, chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq), ChIP-qPCR, and dual-luciferase reporter assays were employed to define the transcriptional regulation of stimulator of interferon genes (STING) by AKNA. A prognostic nomogram integrating AKNA expression with clinicopathological features was developed and externally validated in independent cohorts. Results: AKNA was significantly downregulated in EC tissues compared with normal endometrium, which was associated with advanced International Federation of Gynecology and Obstetrics stage, aggressive histological subtypes, and poor prognosis. AKNA knockdown promoted EC cell proliferation, migration, invasion, and epithelial-mesenchymal transition, while enhancing M2 macrophage polarization and reducing sensitivity to paclitaxel and potentially compromising anti-tumor innate immunity. Conversely, AKNA overexpression or STING activation by cyclic GMP–AMP reversed these malignant phenotypes. Mechanistically, AKNA directly bound to the STING promoter and transcriptionally activated STING, thereby inducing TANK-binding kinase 1 and interferon regulatory factor 3 phosphorylation. The nomogram combining AKNA with clinicopathological features demonstrated high accuracy in predicting EC recurrence and outperformed single-variable models in both training and validation cohorts. Conclusions: AKNA deficiency promotes EC progression by transcriptionally suppressing STING and driving M2 macrophage polarization. AKNA serves as a robust prognostic biomarker and predictive indicator for chemotherapy and innate immune modulation, offering a promising therapeutic target for precision treatment of EC.
- Open Access
- 23 September 2026
- Published by Wiley in Advanced Science
A Metabolic‐Epigenetic Axis of AARS1/IGF2BP3‐K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence
Endometrial cancer (EC) recurrence is strongly associated with enhanced tumor stemness. While lactate—a major tumor‐derived metabolite—is known to promote immunosuppression across cancers, its contribution to EC stemness and recurrence remains poorly understood. In this study, we show that elevated protein lactylation in EC correlates with heightened tumor stemness and unfavorable prognosis. Mechanistically, a lactate‐enriched microenvironment induces lactylation of insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3), thereby stabilizing and upregulating the protein. This modification enhances EC stemness by enabling IGF2BP3 to stabilize HMGA2 mRNA via an m6A‐dependent pathway, activating downstream stemness‐related transcriptional programs. This effect requires lysine 280 (K280) lactylation mediated by alanyl‐tRNA synthetase 1 (AARS1), as either AARS1 depletion or IGF2BP3‐K280 mutation abolishes lactylation and attenuates stemness. Both genetic and pharmacologic inhibition of IGF2BP3 lactylation markedly suppress tumor growth and stem‐like properties in vitro and in vivo. Clinically, IGF2BP3‐K280 lactylation correlates with aggressive clinicopathological features and poor survival, outperforming conventional biomarkers in recurrence prediction. Integration of IGF2BP3‐K280 lactylation into a clinical nomogram substantially improved recurrence‐risk stratification across multi‐center cohorts. Collectively, these findings uncover a metabolic–epigenetic mechanism linking lactate metabolism to m6A‐mediated stemness regulation, establishing IGF2BP3‐K280 lactylation as both a therapeutic vulnerability and a precision biomarker for EC recurrence.
- 23 September 2026
- Published by Wiley in Advanced Science
Open AccessA Metabolic‐Epigenetic Axis of AARS1/IGF2BP3‐K280 Lactylation Sustains Endometrial Cancer Stemness and Recurrence
Endometrial cancer (EC) recurrence is strongly associated with enhanced tumor stemness. While lactate—a major tumor‐derived metabolite—is known to promote immunosuppression across cancers, its contribution to EC stemness and recurrence remains poorly understood. In this study, we show that elevated protein lactylation in EC correlates with heightened tumor stemness and unfavorable prognosis. Mechanistically, a lactate‐enriched microenvironment induces lactylation of insulin‐like growth factor 2 mRNA‐binding protein 3 (IGF2BP3), thereby stabilizing and upregulating the protein. This modification enhances EC stemness by enabling IGF2BP3 to stabilize HMGA2 mRNA via an m6A‐dependent pathway, activating downstream stemness‐related transcriptional programs. This effect requires lysine 280 (K280) lactylation mediated by alanyl‐tRNA synthetase 1 (AARS1), as either AARS1 depletion or IGF2BP3‐K280 mutation abolishes lactylation and attenuates stemness. Both genetic and pharmacologic inhibition of IGF2BP3 lactylation markedly suppress tumor growth and stem‐like properties in vitro and in vivo. Clinically, IGF2BP3‐K280 lactylation correlates with aggressive clinicopathological features and poor survival, outperforming conventional biomarkers in recurrence prediction. Integration of IGF2BP3‐K280 lactylation into a clinical nomogram substantially improved recurrence‐risk stratification across multi‐center cohorts. Collectively, these findings uncover a metabolic–epigenetic mechanism linking lactate metabolism to m6A‐mediated stemness regulation, establishing IGF2BP3‐K280 lactylation as both a therapeutic vulnerability and a precision biomarker for EC recurrence.
- Open Access
- 7 September 2026
- Published by Springer Nature in Scientific Reports
Prognostic nomogram incorporating dynamic SIRI score and clinical parameters to predict postoperative recurrence of endometrial cancer
- 7 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessPrognostic nomogram incorporating dynamic SIRI score and clinical parameters to predict postoperative recurrence of endometrial cancer
- Open Access
- 7 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1862350
A novel nomogram incorporating preoperative systemic inflammatory response index and clinicopathological parameters for predicting lymph node metastasis in endometrial cancer
Objective: This study aimed to evaluate whether preoperative systemic inflammatory response index (SIRI) could predict lymph node metastasis (LNM) in endometrial cancer (EC), and to develop a nomogram that combines SIRI with clinicopathological parameters for individualized LNM risk assessment. Methods: We retrospectively enrolled 1, 336 EC patients who underwent primary surgery. Among them, 947 cases from the First Affiliated Hospital of Chongqing Medical University served as the training cohort, and 389 cases from the Chongqing Maternal and Child Health Hospital comprised the external validation cohort. Preoperative SIRI was calculated using peripheral neutrophil, monocyte, and lymphocyte counts. Logistic regression analyses were used to identify independent predictors of LNM, which were then incorporated into a nomogram. Model performance was evaluated by ROC curves and calibration curves in both cohorts. Kaplan-Meier analysis was applied to compare recurrence-free survival (RFS) and overall survival (OS) between high- and low-risk groups stratified by the model. Results: SIRI yielded an area under the curve (AUC) of 0.773 for predicting LNM, with a sensitivity of 74.2% and specificity of 75.8%. The optimal cutoff value of SIRI was 1.115. Multivariate analysis showed that age, CA125, histological type, molecular classification, and SIRI were independently associated with LNM (P < 0.001). A nomogram integrating these five factors was then constructed. This combined model achieved AUC of 0.889 in the training cohort, outperforming the models based solely on SIRI (AUC = 0.750) or solely on clinicopathological parameters (AUC = 0.836). Calibration curves indicated good agreement between predictions and observations. Using a cutoff of 0.136, we divided patients into high- and low-risk groups and found marked differences in both RFS and OS between training and validation cohorts (P < 0.05). Conclusion: Preoperative SIRI is an independent predictor of LNM in patients with EC. The nomogram model incorporating SIRI and clinicopathological parameters demonstrated superior performance in predicting LNM compared to models containing either SIRI alone or only traditional parameters, providing a valuable tool for individualized preoperative risk stratification and surgical decision-making.
- 7 July 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1862350
Open AccessA novel nomogram incorporating preoperative systemic inflammatory response index and clinicopathological parameters for predicting lymph node metastasis in endometrial cancer
Objective: This study aimed to evaluate whether preoperative systemic inflammatory response index (SIRI) could predict lymph node metastasis (LNM) in endometrial cancer (EC), and to develop a nomogram that combines SIRI with clinicopathological parameters for individualized LNM risk assessment. Methods: We retrospectively enrolled 1, 336 EC patients who underwent primary surgery. Among them, 947 cases from the First Affiliated Hospital of Chongqing Medical University served as the training cohort, and 389 cases from the Chongqing Maternal and Child Health Hospital comprised the external validation cohort. Preoperative SIRI was calculated using peripheral neutrophil, monocyte, and lymphocyte counts. Logistic regression analyses were used to identify independent predictors of LNM, which were then incorporated into a nomogram. Model performance was evaluated by ROC curves and calibration curves in both cohorts. Kaplan-Meier analysis was applied to compare recurrence-free survival (RFS) and overall survival (OS) between high- and low-risk groups stratified by the model. Results: SIRI yielded an area under the curve (AUC) of 0.773 for predicting LNM, with a sensitivity of 74.2% and specificity of 75.8%. The optimal cutoff value of SIRI was 1.115. Multivariate analysis showed that age, CA125, histological type, molecular classification, and SIRI were independently associated with LNM (P < 0.001). A nomogram integrating these five factors was then constructed. This combined model achieved AUC of 0.889 in the training cohort, outperforming the models based solely on SIRI (AUC = 0.750) or solely on clinicopathological parameters (AUC = 0.836). Calibration curves indicated good agreement between predictions and observations. Using a cutoff of 0.136, we divided patients into high- and low-risk groups and found marked differences in both RFS and OS between training and validation cohorts (P < 0.05). Conclusion: Preoperative SIRI is an independent predictor of LNM in patients with EC. The nomogram model incorporating SIRI and clinicopathological parameters demonstrated superior performance in predicting LNM compared to models containing either SIRI alone or only traditional parameters, providing a valuable tool for individualized preoperative risk stratification and surgical decision-making.
- Open Access
- 24 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71876
A Novel Nomogram Incorporating the Aggregate Index of Systemic Inflammation, Clinicopathological Parameters and Molecular Classification to Predict Recurrence of Endometrial Cancer: A Multi‐Center Retrospective Study
This study evaluated the aggregate index of systemic inflammation (AISI) for predicting postoperative recurrence in endometrial cancer (EC). A total of 1557 patients were enrolled and divided into training ( n = 1030) and validation ( n = 527) cohorts. The optimal AISI cutoff was determined by ROC curve analysis. Multivariate Cox regression identified eight independent prognostic factors for recurrence‐free survival (all p < 0.05): age ≥ 60 (HR = 1.683, 95% CI 1.191–2.377), FIGO stage III (HR = 2.346, 95% CI 1.480–3.718), LVSI (HR = 1.792, 95% CI 1.226–2.618), CA125 ≥ 35 U/mL (HR = 1.457, 95% CI 1.030–2.062), deep myometrial invasion (HR = 2.021, 95% CI 1.393–2.930), histological type II (HR = 1.798, 95% CI 1.219–2.653), p53 abnormal (HR = 3.252, 95% CI 2.142–4.936), and high AISI (HR = 2.492, 95% CI 1.714–3.625). A prognostic nomogram incorporating these factors was constructed and validated, demonstrating superior predictive accuracy compared to conventional methods. Adjuvant therapy significantly improved outcomes in high‐risk patients identified by the nomogram. This comprehensive tool enhances risk stratification and may guide personalized treatment planning.
- 24 April 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71876
Open AccessA Novel Nomogram Incorporating the Aggregate Index of Systemic Inflammation, Clinicopathological Parameters and Molecular Classification to Predict Recurrence of Endometrial Cancer: A Multi‐Center Retrospective Study
This study evaluated the aggregate index of systemic inflammation (AISI) for predicting postoperative recurrence in endometrial cancer (EC). A total of 1557 patients were enrolled and divided into training ( n = 1030) and validation ( n = 527) cohorts. The optimal AISI cutoff was determined by ROC curve analysis. Multivariate Cox regression identified eight independent prognostic factors for recurrence‐free survival (all p < 0.05): age ≥ 60 (HR = 1.683, 95% CI 1.191–2.377), FIGO stage III (HR = 2.346, 95% CI 1.480–3.718), LVSI (HR = 1.792, 95% CI 1.226–2.618), CA125 ≥ 35 U/mL (HR = 1.457, 95% CI 1.030–2.062), deep myometrial invasion (HR = 2.021, 95% CI 1.393–2.930), histological type II (HR = 1.798, 95% CI 1.219–2.653), p53 abnormal (HR = 3.252, 95% CI 2.142–4.936), and high AISI (HR = 2.492, 95% CI 1.714–3.625). A prognostic nomogram incorporating these factors was constructed and validated, demonstrating superior predictive accuracy compared to conventional methods. Adjuvant therapy significantly improved outcomes in high‐risk patients identified by the nomogram. This comprehensive tool enhances risk stratification and may guide personalized treatment planning.
- Open Access
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
The prognostic significance of JAML and its role in remodeling the immune microenvironment via the cGAS-STING pathway in endometrial cancer
Background: Endometrial cancer (EC) is a major gynecological malignancy with a poor prognosis in the advanced stages. Junctional adhesion molecule-like protein (JAML) is gaining attention in cancer biology; however, its role in EC remains unclear. Methods: This study integrated multi-omics data (TCGA, pan-cancer analysis and single-cell transcriptomics), dual independent clinical cohorts (TCGA dataset and an institutional cohort), and in vitro / in vivo experimental models to systematically analyze JAML expression patterns, clinical relevance, and tumor-progression regulatory mechanisms in EC. Experimental approaches included: immunohistochemistry (IHC), qRT-PCR, and Western blotting for expression validation; shRNA knockdown, Transwell/scratch assays, CCK-8 assays, and conditioned medium co-culture models for functional analysis; bioinformatics tools (ESTIMATE, TIMER, MCP-counter) and flow cytometry for immune microenvironment evaluation; drug sensitivity analysis (Genomics of Drug Sensitivity in Cancer (GDSC)/Tumor Immune Dysfunction and Exclusion (TIDE) databases) and prognostic modeling (Cox regression/nomogram) for clinical application assessment. Results: In EC, JAML expression was significantly downregulated and correlated with poor prognosis. JAML knockdown promoted cancer cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) (all P < 0.01), accompanied by reduced stimulator of interferon genes (STING) phosphorylation (P < 0.01). Low JAML expression correlated with decreased M1 (CD86 + , P < 0.01) and increased M2 (CD206 + , P < 0.01) macrophage infiltration. It was also linked to reduced cisplatin/paclitaxel sensitivity (P < 0.05) and lower immunotherapy response (29.04% vs. 45.05%, P = 0.015). STING agonist cyclic GMP–AMP (cGAMP) partially restored M1 infiltration and chemosensitivity after JAML knockdown in vitro . A nomogram incorporating JAML and clinicopathological parameters showed improved predictive performance (AUC 0.885; cutoff 0.882; sensitivity 0.818, specificity 0.820), with calibration curves confirming good agreement between predicted and observed recurrence. Conclusions: These findings suggest that JAML deficiency may suppress cyclic GMP-AMP synthase (cGAS)-STING pathway activation, potentially contributing to M1/M2 macrophage polarization imbalance and facilitating EC progression. Clinically, JAML expression shows promise as a potential biomarker for prognostic stratification and treatment response prediction (chemotherapy/immunotherapy), providing insights for developing precision immunochemotherapy strategies in EC.
- 29 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Open AccessThe prognostic significance of JAML and its role in remodeling the immune microenvironment via the cGAS-STING pathway in endometrial cancer
Background: Endometrial cancer (EC) is a major gynecological malignancy with a poor prognosis in the advanced stages. Junctional adhesion molecule-like protein (JAML) is gaining attention in cancer biology; however, its role in EC remains unclear. Methods: This study integrated multi-omics data (TCGA, pan-cancer analysis and single-cell transcriptomics), dual independent clinical cohorts (TCGA dataset and an institutional cohort), and in vitro / in vivo experimental models to systematically analyze JAML expression patterns, clinical relevance, and tumor-progression regulatory mechanisms in EC. Experimental approaches included: immunohistochemistry (IHC), qRT-PCR, and Western blotting for expression validation; shRNA knockdown, Transwell/scratch assays, CCK-8 assays, and conditioned medium co-culture models for functional analysis; bioinformatics tools (ESTIMATE, TIMER, MCP-counter) and flow cytometry for immune microenvironment evaluation; drug sensitivity analysis (Genomics of Drug Sensitivity in Cancer (GDSC)/Tumor Immune Dysfunction and Exclusion (TIDE) databases) and prognostic modeling (Cox regression/nomogram) for clinical application assessment. Results: In EC, JAML expression was significantly downregulated and correlated with poor prognosis. JAML knockdown promoted cancer cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) (all P < 0.01), accompanied by reduced stimulator of interferon genes (STING) phosphorylation (P < 0.01). Low JAML expression correlated with decreased M1 (CD86 + , P < 0.01) and increased M2 (CD206 + , P < 0.01) macrophage infiltration. It was also linked to reduced cisplatin/paclitaxel sensitivity (P < 0.05) and lower immunotherapy response (29.04% vs. 45.05%, P = 0.015). STING agonist cyclic GMP–AMP (cGAMP) partially restored M1 infiltration and chemosensitivity after JAML knockdown in vitro . A nomogram incorporating JAML and clinicopathological parameters showed improved predictive performance (AUC 0.885; cutoff 0.882; sensitivity 0.818, specificity 0.820), with calibration curves confirming good agreement between predicted and observed recurrence. Conclusions: These findings suggest that JAML deficiency may suppress cyclic GMP-AMP synthase (cGAS)-STING pathway activation, potentially contributing to M1/M2 macrophage polarization imbalance and facilitating EC progression. Clinically, JAML expression shows promise as a potential biomarker for prognostic stratification and treatment response prediction (chemotherapy/immunotherapy), providing insights for developing precision immunochemotherapy strategies in EC.
- 8 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1109-1119
Nomogram Based on Pan-Immune Inflammation Value and Clinicopathological Parameters for Predicting the Recurrence of Endometrial Cancer and Providing Postoperative Prognostic Management
Evaluation of preoperative pan-immune inflammation value (PIV) combined with clinicopathological parameters in predicting postoperative recurrence of endom
- 8 November 2025
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (2) , 1109-1119
Nomogram Based on Pan-Immune Inflammation Value and Clinicopathological Parameters for Predicting the Recurrence of Endometrial Cancer and Providing Postoperative Prognostic Management
Evaluation of preoperative pan-immune inflammation value (PIV) combined with clinicopathological parameters in predicting postoperative recurrence of endom
- Open Access
- 1 August 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 10559-10572
Nomogram Incorporating Inflammatory Index, Pathology, and Molecular Classification for Predicting Recurrence in Patients with Stage I-III Endometrial Cancer: A Multi-Institutional Study
Background: This study evaluated the prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score for postoperative recurrence in endometrial cancer patients. A nomogram was developed based on clinicopathological parameters, HALP score, and immunohistochemical markers to predict recurrence-free survival (RFS) in patients with stage I–III endometrial cancer. Methods: This retrospective study included 1,083 patients who underwent hysterectomy at the First Affiliated Hospital of Chongqing Medical University from January 2013 to January 2021. Independent risk factors for RFS were identified using univariate and multivariate Cox regression analyses, and a nomogram was established. External validation was performed with data from Zhujiang Hospital of Southern Medical University and Women and Children’s Hospital of Chongqing Medical University (n = 677). Results: Among the entire cohort, 241 cases (13.7%) of endometrial cancer experienced recurrence post-hysterectomy. The median RFS time was 47.0 (range: 6.0– 91.0) months. Eleven independent prognostic factors were identified, including age, FIGO staging, histologic type, myometrial invasion, lymphovascular space invasion, Ca125, Ki-67 expression, ER expression, molecular classification, adjuvant therapy, and HALP score, and then a nomogram for predicting recurrence of endometrial cancer was established. The nomogram demonstrated improved predictive accuracy, categorizing patients into high- and low-risk groups. High-risk patients receiving adjuvant treatment had better outcomes than those who did not. Conclusion: We developed and validated a nomogram to predict recurrence in endometrial cancer patients. Integrating the HALP score can help clinicians identify high-risk patients and tailor personalized treatment strategies.
- 1 August 2025
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 18, 10559-10572
Open AccessNomogram Incorporating Inflammatory Index, Pathology, and Molecular Classification for Predicting Recurrence in Patients with Stage I-III Endometrial Cancer: A Multi-Institutional Study
Background: This study evaluated the prognostic value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score for postoperative recurrence in endometrial cancer patients. A nomogram was developed based on clinicopathological parameters, HALP score, and immunohistochemical markers to predict recurrence-free survival (RFS) in patients with stage I–III endometrial cancer. Methods: This retrospective study included 1,083 patients who underwent hysterectomy at the First Affiliated Hospital of Chongqing Medical University from January 2013 to January 2021. Independent risk factors for RFS were identified using univariate and multivariate Cox regression analyses, and a nomogram was established. External validation was performed with data from Zhujiang Hospital of Southern Medical University and Women and Children’s Hospital of Chongqing Medical University (n = 677). Results: Among the entire cohort, 241 cases (13.7%) of endometrial cancer experienced recurrence post-hysterectomy. The median RFS time was 47.0 (range: 6.0– 91.0) months. Eleven independent prognostic factors were identified, including age, FIGO staging, histologic type, myometrial invasion, lymphovascular space invasion, Ca125, Ki-67 expression, ER expression, molecular classification, adjuvant therapy, and HALP score, and then a nomogram for predicting recurrence of endometrial cancer was established. The nomogram demonstrated improved predictive accuracy, categorizing patients into high- and low-risk groups. High-risk patients receiving adjuvant treatment had better outcomes than those who did not. Conclusion: We developed and validated a nomogram to predict recurrence in endometrial cancer patients. Integrating the HALP score can help clinicians identify high-risk patients and tailor personalized treatment strategies.
- Open Access
- 1 December 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 11437-11449
Nomogram Based on Immune-Inflammatory Score and Classical Clinicopathological Parameters for Predicting the Recurrence of Endometrial Carcinoma: A Large, Multi-Center Retrospective Study
Background: Surgery is the best approach to treat endometrial cancer (EC); however, there is currently a deficiency in effective scoring systems for predicting EC recurrence post-surgical resection. This study aims to develop a clinicopathological-inflammatory parameters-based nomogram to accurately predict the postoperative recurrence-free survival (RFS) rate of EC patients. Methods: A training set containing 1068 patients and an independent validation set consisting of 537 patients were employed in this retrospective study. The prognostic factors for RFS were identified by univariable and multivariable Cox proportional hazards regression analyses, and integrated into nomogram. The C-index, area under the curves (AUC), and calibration curves were employed to determine the predictive discriminability and accuracy of nomogram. Utilizing the nomogram, patients were stratified into low- and high-risk groups, and the Kaplan-Meier survival curve was further employed to assess the clinical efficacy of the model. Results: Cox regression analyses revealed that age (HR = 1.769, P = 0.002), FIGO staging (HR = 1.790, P = 0.018), LVSI (HR = 1.654, P = 0.017), Ca125 (HR = 1.532, P = 0.023), myometrial invasion (HR = 1.865, P = 0.001), cervical stromal invasion (HR = 1.655, P = 0.033), histology (HR = 2.637, P < 0.001), p53 expression (HR = 1.706, P = 0.002), PLR (HR = 1.971, P = 0.003), SIRI (HR = 2.187, P = 0.003), and adjuvant treatment (HR = 0.521, P = 0.003) were independent prognostic factors for RFS in patients with EC. A combined clinicopathologic-inflammatory parameters model was constructed, which outperformed the single-indicator model and other established models in predicting the 1-, 3-, and 5-year RFS rates in patients with EC. Conclusion: The nomogram demonstrated sufficient accuracy in predicting the RFS probabilities of EC, enabling personalized clinical decision-making for future clinical endeavors.
- 1 December 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 11437-11449
Open AccessNomogram Based on Immune-Inflammatory Score and Classical Clinicopathological Parameters for Predicting the Recurrence of Endometrial Carcinoma: A Large, Multi-Center Retrospective Study
Background: Surgery is the best approach to treat endometrial cancer (EC); however, there is currently a deficiency in effective scoring systems for predicting EC recurrence post-surgical resection. This study aims to develop a clinicopathological-inflammatory parameters-based nomogram to accurately predict the postoperative recurrence-free survival (RFS) rate of EC patients. Methods: A training set containing 1068 patients and an independent validation set consisting of 537 patients were employed in this retrospective study. The prognostic factors for RFS were identified by univariable and multivariable Cox proportional hazards regression analyses, and integrated into nomogram. The C-index, area under the curves (AUC), and calibration curves were employed to determine the predictive discriminability and accuracy of nomogram. Utilizing the nomogram, patients were stratified into low- and high-risk groups, and the Kaplan-Meier survival curve was further employed to assess the clinical efficacy of the model. Results: Cox regression analyses revealed that age (HR = 1.769, P = 0.002), FIGO staging (HR = 1.790, P = 0.018), LVSI (HR = 1.654, P = 0.017), Ca125 (HR = 1.532, P = 0.023), myometrial invasion (HR = 1.865, P = 0.001), cervical stromal invasion (HR = 1.655, P = 0.033), histology (HR = 2.637, P < 0.001), p53 expression (HR = 1.706, P = 0.002), PLR (HR = 1.971, P = 0.003), SIRI (HR = 2.187, P = 0.003), and adjuvant treatment (HR = 0.521, P = 0.003) were independent prognostic factors for RFS in patients with EC. A combined clinicopathologic-inflammatory parameters model was constructed, which outperformed the single-indicator model and other established models in predicting the 1-, 3-, and 5-year RFS rates in patients with EC. Conclusion: The nomogram demonstrated sufficient accuracy in predicting the RFS probabilities of EC, enabling personalized clinical decision-making for future clinical endeavors.